ArticlePloS one2026
Direct medical costs of respiratory infections in adults: A multicenter retrospective analysis in Thai Nguyen, Vietnam.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory infections remain a significant health and economic burden in low- and middle-income countries, including Vietnam. This study aimed to estimate the direct medical costs of respiratory infections among adults in Thai Nguyen, Vietnam and identify some influencing factors.
methodsIn this retrospective study, we analyzed direct medical costs of inpatient aged ≥18 discharged with respiratory infections (ICD-10 codes: J00 - J22) in seven hospitals in Thai Nguyen, Vietnam. Records of patients admitted between 11 November 2022 and 30 June 2025 were included. A generalized gamma linear mixed model with log-link function was used to identify influencing factors, including patient demographics and infection-related characteristics. All costs are expressed in US$, adjusted to 2025 levels.
resultsThe analysis included 25,081 inpatients with 28,016 respiratory infection episodes. Most were female (54.3%), Kinh ethnicity (70.0%), and aged ≥60 (58.1%). Pneumonia (J18) was the most common primary diagnosis (58.5%), followed by bacterial pneumonia (J15, 18.7%). Common secondary diagnoses included hypertension (27.1%), gastro-oesophageal reflux disease (7.8%), and type 2 diabetes (6.9%). The median total medical cost per inpatient episode was US$174.9 (IQR 104.7-243.3), mainly driven by hospital bed days (median US$83.5), followed by medicine costs (US$52.7), and laboratory tests (US$12.7). Pneumonia was the most expensive disease, with median costs of US$218.8 (J15), US$1,179.4 (J16), and US$181.5 (J18). Primary diagnosis, age, gender, hospital level, length of stay, and additional secondary diagnosis were associated with higher direct medical costs.
conclusionHospitalized adults with respiratory infections incurred a median direct medical cost of US$174.9 in Thai Nguyen, Vietnam. Costs were substantially higher for lower respiratory tract infections and were influenced by hospital level, length of stay, and comorbidities. These findings highlight the need for preventive measures and efficient hospital resource allocation in Vietnam.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.